Медицинский вестник Юга России (Oct 2018)

Clinical and prognostic value of determining the level of neopterin in patients with chronic heart failure with preserved ejection fraction

  • O. S. Polunina,
  • L. P. Voronina,
  • I. V. Sevostyanova,
  • E. A. Polunina

DOI
https://doi.org/10.21886/2219-8075-2018-9-3-84-89
Journal volume & issue
Vol. 9, no. 3
pp. 84 – 89

Abstract

Read online

Objective: to analyze the level of neopterin in patients with chronic heart failure (CHF) with a preserved fraction ejection fraction depending on the stage of the disease. Materials and methods: were examined 148 patients with CHF with preserved ejection fraction (50% and >) and 30 as a control group. Patients with CHF were divided into groups depending on the stage of CHF (from I to III). The level of neopterine was determined by the method of enzyme immunoassay in blood plasma. Results: in patients with CHF with preserved ejection fraction there was a tendency to increase the level of neopterin from stage I to stage III compared to the control group. In the group of patients with CHF IIB+III the level of neoplasm was statistically slightly lower compared to patients of stage I and IIA, but statistically signifi cantly higher than in the control group. Conclusion: it was revealed the change in the level of neopterin in patients with CHS with retained ejection fraction depending on the stage of the disease.

Keywords